A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWERCSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6
Por:
Hughes BGM, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, Grob JJ, Lewis KD, Ansstas G, Day F, Ladwa R, Stein BN, Muñoz Couselo E, Meier F, Hauschild A, Schadendorf D, Basset-Seguin N, Modi B, Dalac-Rat S, Dunn LA, Flatz L, Mortier L, Guégan S, Heinzerling LM, Mehnert JM, Trabelsi S, Soria-Rivas A, Stratigos AJ, Ulrich C, Wong DJ, Beylot-Barry M, Bossi P, Bugés Sánchez C, Chandra S, Robert C, Russell JS, Silk AW, Booth J, Yoo SY, Seebach F, Lowy I, Fury MG and Rischin D
Publicada:
1 ene 2025
Ahead of Print:
1 dic 2024
Resumen:
Background: In the phase 2 EMPOWER-CSCC-1 study (NCT02760498), cemiplimab demonstrated antitumor activity against metastatic cutaneous squamous cell carcinoma (mCSCC) and locally advanced cutaneous squamous cell carcinoma (laCSCC). Objectives: To report final analysis of weight-based cemiplimab in mCSCC and laCSCC (groups 1 and 2), fixed-dose cemiplimab in mCSCC (group 3), and primary analysis of fixed-dose cemiplimab in mCSCC/laCSCC (group 6). Methods: Patients received cemiplimab (3 mg/kg intravenously every 2 weeks [groups 1 and 2]) or cemiplimab (350 mg intravenously [groups 3 and 6]) every 3 weeks. The primary end point was objective response rate (ORR). Duration of response (DOR) and progression-free survival (PFS) are presented per protocol, according to post-hoc sensitivity analyses that only include the period of protocol-mandated imaging assessments. Results: At 42.5 months, ORR for groups 1-3 (n = 193) was 47.2%, estimated 12-month DOR was 88.3%, and median PFS was 26.0 months. At 8.7 months, ORR for group 6 (n = 165 patients) was 44.8%; median DOR and median PFS were not reached. Serious treatment-emergent adverse event rates (grade $ 3) were groups 1-3: 31.1% and group 6: 34.5%. Limitations: Nonrandomized study, nonsurvival primary end point. Conclusion: EMPOWER-CSCC-1 provides the largest prospective data on long-term efficacy and safety for anti-programmed cell death-1 therapy in advanced CSCC.
Filiaciones:
Hughes BGM:
Department of Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia
Guminski A:
Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia
Bowyer S:
Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
Migden MR:
Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas
Schmults CD:
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
Khushalani NI:
Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida
Chang ALS:
Department of Dermatology, Stanford University School of Medicine, Redwood City, California
Grob JJ:
Aix Marseille University, Hôpital de la Timone, Marseille, France
Lewis KD:
University of Colorado Denver Cancer Center, Aurora, Colorado
Ansstas G:
Department of Surgical Oncology, Washington University School of Medicine, St Louis, Missouri
Day F:
Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia
Ladwa R:
Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Stein BN:
Adelaide Cancer Centre, Adelaide, South Australia, Australia
Muñoz Couselo E:
Department of Medical Oncology, Melanoma and Other Skin Tumors Unit, Vall d'Hebron University Hospital, Barcelona, Spain
Meier F:
Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
Skin Cancer Center at the University Cancer Centre and National Center for Tumor Diseases, Dresden, Germany
Hauschild A:
Department of Dermatology, University Hospital (UKSH), Kiel, Germany
Schadendorf D:
Department of Dermatology, University Hospital of Essen, Essen, Germany
German Cancer Consortium, Partner Site Essen, NCT-West, Campus Essen and University Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany
Basset-Seguin N:
Hôpital Saint-Louis, Paris, France
Modi B:
Division of Dermatology, Department of Surgery, City of Hope, Duarte, California
Dalac-Rat S:
Hospital Center University Dijon Bourgogne, Dijon, France
Dunn LA:
David H. Koch Center for Cancer Care, Memorial Sloan Kettering Cancer Center, New York, New York
Flatz L:
University Hospital Tübingen, Tübingen, Germany
Mortier L:
Centre Hospitalier Régional Universitaire de Lille (CHRU), Lille, France
Guégan S:
Department of Dermatology, Hôpital Cochin, Paris, France
Heinzerling LM:
Department of Dermatology, LMU University Hospital Munich, Munich, Germany
Department of Dermatology, University Hospital Erlangen, Erlangen, Germany
Mehnert JM:
Melanoma and Cutaneous Medical Oncology, Perlmutter Cancer Center, NY University, Langone Health, New York, New York
Trabelsi S:
CHU de Grenoble - Hôpital A Michallon, Grenoble, France
Soria-Rivas A:
Ramón y Cajal University Hospital, Spanish Society of Medical Oncology (SEOM), Madrid, Spain
Stratigos AJ:
First Department of Dermatology-Venereology, Andreas Sygros Hospital, Athens, Greece
National and Kapodistrian University of Athens Medical School, Athens, Greece
Ulrich C:
Charite-Universitatsmedizin Berlin, Berlin, Germany
Wong DJ:
UCLA Department of Medicine, Los Angeles, California
Beylot-Barry M:
Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France
Bossi P:
Department of Biomedical Sciences, Humanitas University, Milan, Italy
IRCCS Humanitas Research Hospital, Milan, Italy
:
Department of Medical Oncology, Skin Tumors Unit, Catalan Institute of Oncology, Germans Trias i Pujol University Hospital, Barcelona, Spain
Badalona-Applied Research Group in Oncology (B-ARGO), Badalona, Barcelona, Spain
Chandra S:
Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
Robert C:
Gustave Roussy Cancer Center, Villejuif, France
Russell JS:
Head and Neck/Cutaneous Medical Oncology, Huntsman Cancer Institute, Salt Lake City, Utah
Silk AW:
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
Booth J:
Regeneron Pharmaceuticals, Inc., Tarrytown, New York
Yoo SY:
Regeneron Pharmaceuticals, Inc., Tarrytown, New York
Seebach F:
Regeneron Pharmaceuticals, Inc., Tarrytown, New York
Lowy I:
Regeneron Pharmaceuticals, Inc., Tarrytown, New York
Fury MG:
Regeneron Pharmaceuticals, Inc., Tarrytown, New York
Rischin D:
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
|